Novo Nordisk (NVO) stated its semagutide 25 mg achieved 3% more weight loss than Eli Lilly's orforglipron. However, orforglipron showed 14x higher GI-related discontinuation rates. 84% of patients preferred Novo's treatment profile. NVO stock fell 1.8%, while Eli Lilly dipped 1% following the FDA approval of Lilly's rival drug.